The SARS‐CoV‐2 main protease (M pro ): Structure, function, and emerging therapies for COVID‐19

Abstract

The main proteases (M pro ), also termed 3‐chymotrypsin‐like proteases (3CL pro ), are a class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has demonstrated that 3CL pro s play an indispensable role in viral replication and have been recognized as key targets for preventing and treating coronavirus‐caused infectious diseases, including COVID‐19. This review is focused on the structural features and biological function of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) main protease M pro (also known as 3CL pro ), as well as recent advances in discovering and developing SARS‐CoV‐2 3CL pro inhibitors. To better understand the characteristics of SARS‐CoV‐2 3CL pro inhibitors, the inhibition activities, inhibitory mechanisms, and key structural features of various 3CL pro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives) are summarized comprehensively. Meanwhile, the challenges in this field are highlighted, while future directions for designing and developing efficacious 3CL pro inhibitors as novel anti‐coronavirus therapies are also proposed. Collectively, all information and knowledge presented here are very helpful for understanding the structural features and inhibitory mechanisms of SARS‐CoV‐2 3CL pro inhibitors, which offers new insights or inspiration to medicinal chemists for designing and developing more efficacious 3CL pro inhibitors as novel anti‐coronavirus agents.

References 325

1. 1.

   Artika IM, Dewantari AK, Wiyatno A. Molecular biology of coronaviruses: current knowledge. Heliyon. 2020;6(8):e04743.

   Not in our library10.1016/j.heliyon.2020.e04743

2. 2.

   Gorbalenya AE, Enjuanes L, Ziebuhr J, et al. Nidovirales: evolving the largest RNA virus genome. Virus Res. 2006;117(1):17‐37.

   Not in our library10.1016/j.virusres.2006.01.017

3. 3.

   Mirza MU, Froeyen M. Structural elucidation of SARS‐CoV‐2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J Pharm Anal. 2020;10(4):320‐328.

   Not in our library10.1016/j.jpha.2020.04.008

4. 4.

   Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus‐EMC. Nature. 2013;495(7440):251‐254.

   Not in our library10.1038/nature12005

5. 5.

   Wang Y, Grunewald M, Perlman S. Coronaviruses: an updated overview of their replication and pathogenesis. Methods Mol Biol. 2020;2203:1‐29.

   Not in our library10.1007/978-1-0716-0900-2_1

6. 6.

   Zuniga S, Sola I, Alonso S, et al. Sequence motifs involved in the regulation of discontinuous coronavirus subgenomic RNA synthesis. J Virol. 2004;78(2):980‐994.

   Not in our library10.1128/jvi.78.2.980-994.2004

7. 7.

   Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus‐infected pneumonia. N Engl J Med. 2020;382(13):1199‐1207.

   Not in our library10.1056/nejmoa2001316

8. 8.

   Mitsuya H, Kokudo N. Sustaining containment of COVID‐19: global sharing for pandemic response. Glob Health Med. 2020;2(2):53‐55.

   Not in our library10.35772/ghm.2020.01040

9. 9.

   Tu H, Tu S, Gao S, et al. Current epidemiological and clinical features of COVID‐19; a global perspective from China. J Infect. 2020;81(1):1‐9.

   Not in our library10.1016/j.jinf.2020.04.011

10. 10.

    Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727‐733.

    Not in our library10.1056/nejmoa2001017

11. 11.

    Alderson MR, Arkwright PD, Bai X, et al. Surveillance and control of meningococcal disease in the COVID‐19 era: a global meningococcal initiative review. J Infect. 2022;84(3):289‐296.

    Not in our library10.1016/j.jinf.2021.11.016

12. 12.

    Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID‐19. J Pharm Anal. 2020;10(2):102‐108.

    Not in our library10.1016/j.jpha.2020.03.001

13. 13.

    Ramos‐Guzman CA, Ruiz‐Pernia JJ, Tunon I. Multiscale simulations of SARS‐CoV‐2 3CL protease inhibition with aldehyde derivatives. Role of protein and inhibitor conformational changes in the reaction mechanism. ACS Catal. 2021;11(7):4157‐4168.

    Not in our library10.1021/acscatal.0c05522

14. 14.

    Xie X, Hu L, Xue H, et al. Prognosis and treatment of complications associated with COVID‐19: a systematic review and meta‐analysis. Acta Mater Med. 2022;1(1).

    Not in our library

15. 15.

    Gurung AB, Ali MA, Lee J, et al. Structural and functional insights into the major mutations of SARS‐CoV‐2 spike RBD and its interaction with human ACE2 receptor. J King Saud Univ Sci. 2022;34(2):101773.

    Not in our library10.1016/j.jksus.2021.101773

16. 16.

    Jin Z, Du X, Xu Y, et al. Structure of M(pro) from SARS‐CoV‐2 and discovery of its inhibitors. Nature. 2020;582(7811):289‐293.

    Not in our library10.1038/s41586-020-2223-y

17. 17.

    Berkhout B, Herrera‐Carrillo E. SARS‐CoV‐2 evolution: on the sudden appearance of the Omicron variant. J Virol. 2022;96(7):e0009022.

    Not in our library10.1128/jvi.00090-22

18. 18.

    del Rio C, Omer SB, Malani PN. Winter of Omicron—the evolving COVID‐19 pandemic. JAMA. 2022;327(4):319‐320.

    Not in our library10.1001/jama.2021.24315

19. 19.

    Li Q, Kang C. Progress in developing inhibitors of SARS‐CoV‐2 3C‐like protease. Microorganisms. 2020;8(8):1250.

    Not in our library10.3390/microorganisms8081250

20. 20.

    Tian D, Sun YH, Zhou JM, et al. The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape. J Med Virol. 2022;94(3):847‐857.

    Not in our library10.1002/jmv.27376

21. 21.
    SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model · 2021

    No notice
22. 22.

    Anand K, Palm GJ, Mesters JR, et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha‐helical domain. EMBO J. 2002;21(13):3213‐3224.

    Not in our library10.1093/emboj/cdf327

23. 23.

    He J, Hu L, Huang X, et al. Potential of coronavirus 3C‐like protease inhibitors for the development of new anti‐SARS‐CoV‐2 drugs: insights from structures of protease and inhibitors. Int J Antimicrob Agents. 2020;56(2):106055.

    Not in our library10.1016/j.ijantimicag.2020.106055

24. 24.

    Pillaiyar T, Manickam M, Namasivayam V, et al. An overview of severe acute respiratory syndrome‐coronavirus (SARS‐CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem. 2016;59(14):6595‐6628.

    Not in our library10.1021/acs.jmedchem.5b01461

25. 25.
    Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors · 2020

    No notice
26. 26.

    Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus‐encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol. 2000;81(Pt 4):853‐879.

    Not in our library10.1099/0022-1317-81-4-853

27. 27.

    Cui W, Cui S, Chen C, et al. The crystal structure of main protease from mouse hepatitis virus A59 in complex with an inhibitor. Biochem Biophys Res Commun. 2019;511(4):794‐799.

    Not in our library10.1016/j.bbrc.2019.02.105

28. 28.

    Galasiti Kankanamalage AC, Kim Y, Damalanka VC, et al. Structure‐guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur J Med Chem. 2018;150:334‐346.

    Not in our library10.1016/j.ejmech.2018.03.004

29. 29.

    Kanitz M, Blanck S, Heine A, et al. Structural basis for catalysis and substrate specificity of a 3C‐like cysteine protease from a mosquito mesonivirus. Virology. 2019;533:21‐33.

    Not in our library10.1016/j.virol.2019.05.001

30. 30.
    Structural Basis of Inhibition Specificities of 3C and 3C-like Proteases by Zinc-coordinating and Peptidomimetic Compounds · 2009

    No notice
31. 31.

    St John SE, Tomar S, Stauffer SR, et al. Targeting zoonotic viruses: structure‐based inhibition of the 3C‐like protease from bat coronavirus HKU4 – the likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS). Bioorg Med Chem. 2015;23(17):6036‐6048.

    Not in our library10.1016/j.bmc.2015.06.039

32. 32.

    Tian X, Lu G, Gao F, et al. Structure and cleavage specificity of the chymotrypsin‐like serine protease (3CLSP/nsp4) of porcine reproductive and respiratory syndrome virus (PRRSV). J Mol Biol. 2009;392(4):977‐993.

    Not in our library10.1016/j.jmb.2009.07.062

33. 33.

    Wang F, Chen C, Liu X, et al. Crystal structure of feline infectious peritonitis virus main protease in complex with synergetic dual inhibitors. J Virol. 2016;90(4):1910‐1017.

    Not in our library10.1128/jvi.02685-15

34. 34.

    Wang F, Chen C, Yang K, et al. Michael acceptor‐based peptidomimetic inhibitor of main protease from porcine epidemic diarrhea virus. J Med Chem. 2017;60(7):3212‐3216.

    Not in our library10.1021/acs.jmedchem.7b00103

35. 35.

    Xue X, Yu H, Yang H, et al. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol. 2008;82(5):2515‐2527.

    Not in our library10.1128/jvi.02114-07

36. 36.

    Yang H, Yang M, Ding Y, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A. 2003;100(23):13190‐13195.

    Not in our library10.1073/pnas.1835675100

37. 37.

    Zhao Q, Li S, Xue F, et al. Structure of the main protease from a global infectious human coronavirus, HCoV‐HKU1. J Virol. 2008;82(17):8647‐8655.

    Not in our library10.1128/jvi.00298-08

38. 38.

    Shagufta Ahmad I. The race to treat COVID‐19: potential therapeutic agents for the prevention and treatment of SARS‐CoV‐2. Eur J Med Chem. 2021;213:113157.

    Not in our library10.1016/j.ejmech.2021.113157

39. 39.
    Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods · 2020

    Not checked
40. 40.

    Liu Y, Liang C, Xin L, et al. The development of coronavirus 3C‐Like protease (3CL(pro)) inhibitors from 2010 to 2020. Eur J Med Chem. 2020;206:112711.

    Not in our library10.1016/j.ejmech.2020.112711

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.